Alnylam Pharmaceuticals (ALNY) traded higher Tuesday, March 31, 2026, with the move tied to continued post-event positioning after the company’s March 24 “TTR Investor Webinar,” which refocused attention on the commercial ramp of AMVUTTRA in ATTR cardiomyopathy (ATTR-CM) and the broader transthyretin (TTR) franchise. The webinar timing and message have been cited as a key driver of renewed buying interest in the stock following recent volatility in large-cap biotech.

Alnylam’s investor materials highlight the TTR franchise as the company’s primary near-term value driver, and the March 24 webcast kept the spotlight on AMVUTTRA’s ATTR-CM opportunity and longer-term lifecycle strategy. Traders appear to be treating the webinar as a re-anchoring event for expectations around market penetration and growth durability, which can translate into incremental buying as investors revisit forward sales and margin trajectories.

In the days around the webinar, multiple analyst notes reiterated bullish stances and maintained elevated price targets, reinforcing the view that AMVUTTRA’s ATTR-CM ramp can support faster earnings power over time. With the stock trading near $326, reiterations of Buy/Overweight calls and targets well above the current price have helped keep sentiment constructive even without a single new headline this morning.

Investors will be watching for fresh datapoints on AMVUTTRA prescription momentum, payer dynamics, and competitive positioning in ATTR-CM as the market becomes more crowded. Any additional guidance commentary, conference appearances, or updates that narrow uncertainty around 2026 revenue and profitability cadence could quickly become the next tradable catalyst.